{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:25:01Z","timestamp":1787675101557,"version":"build-2784847793"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":216,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clinical trials of medication for psychosis focus on symptom reduction or relapse as the primary outcome. Broader consumer definitions of recovery that emphasize quality of life, functioning, and treatment tolerability are rarely incorporated into primary trial outcomes. The aim was to co-design a Desirability of Outcome Ranking (DOOR), a novel primary outcome that integrates multiple consumer and clinician priorities in relation to antipsychotic medication trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design<\/jats:title>\n                    <jats:p>Through an iterative co-design process, clinicians and consumers (young people and families with lived experience of psychosis) first rated outcomes of greatest personal and clinical importance for medication trials. The top three were quality of life, clinical symptoms, and side effects. Consumers then completed a preliminary survey, co-design focus groups, and written feedback to create the DOOR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Results<\/jats:title>\n                    <jats:p>A final DOOR with 48 ordinal levels was created. Consumers prioritized quality of life, but only when symptoms and\/or side effects remained within tolerable (mild\u2013moderate) ranges. Levels 1-12 represented the most desirable outcomes, characterized by high\/moderate quality of life with minimal-to-mild symptoms\/side effects. Levels 13-24 reflected moderate\/high quality of life with a mixture of symptom\/side-effect outcomes. Levels 25-36 reflected low\/moderate quality of life with generally lower symptoms\/side effects. Levels 37-48 were least desirable, characterized by low\/moderate quality of life with generally moderate\/severe symptoms\/side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This co-designed novel DOOR integrates multiple consumer and clinician preferred constructs into a single holistic outcome. Examining its performance and interpretability in clinical trials of medication for psychosis is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/schizbullopen\/sgag033","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:19:20Z","timestamp":1785755960000},"source":"Crossref","is-referenced-by-count":0,"title":["Co-Design of a Novel Desirability of Outcome Ranking for Medication Trials in Psychosis"],"prefix":"10.1093","volume":"7","author":[{"given":"Alexandra","family":"Stainton","sequence":"first","affiliation":[{"name":"Orygen, The National Centre for Excellence in Youth Mental Health , Parkville, VIC 3052 ,","place":["Australia"]},{"name":"Centre for Youth Mental Health, University of Melbourne , Melbourne, VIC 3052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9807-6606","authenticated-orcid":false,"given":"Leonid","family":"Churilov","sequence":"additional","affiliation":[{"name":"Department of Medicine, Melbourne Medical School, The University of Melbourne , Melbourne, VIC 3052 ,","place":["Australia"]},{"name":"Australian Centre for Accelerating Diabetes Innovations (ACADI), The University of Melbourne , Carlton, VIC 3053 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amity","family":"Albright","sequence":"additional","affiliation":[{"name":"Orygen, The National Centre for Excellence in Youth Mental Health , Parkville, VIC 3052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Barton","sequence":"additional","affiliation":[{"name":"Orygen, The National Centre for Excellence in Youth Mental Health , Parkville, VIC 3052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Curtain","sequence":"additional","affiliation":[{"name":"Orygen, The National Centre for Excellence in Youth Mental Health , Parkville, VIC 3052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janelle","family":"Eggins","sequence":"additional","affiliation":[{"name":"Orygen, The National Centre for Excellence in Youth Mental Health , Parkville, VIC 3052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Lewis","sequence":"additional","affiliation":[{"name":"Orygen, The National Centre for Excellence in Youth Mental Health , Parkville, VIC 3052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"To","sequence":"additional","affiliation":[{"name":"Orygen, The National Centre for Excellence in Youth Mental Health , Parkville, VIC 3052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sav J","family":"Walker","sequence":"additional","affiliation":[{"name":"Orygen, The National Centre for Excellence in Youth Mental Health , Parkville, VIC 3052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barnaby","family":"Nelson","sequence":"additional","affiliation":[{"name":"Orygen, The National Centre for Excellence in Youth Mental Health , Parkville, VIC 3052 ,","place":["Australia"]},{"name":"Centre for Youth Mental Health, University of Melbourne , Melbourne, VIC 3052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Thompson","sequence":"additional","affiliation":[{"name":"Orygen, The National Centre for Excellence in Youth Mental Health , Parkville, VIC 3052 ,","place":["Australia"]},{"name":"Centre for Youth Mental Health, University of Melbourne , Melbourne, VIC 3052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Wood","sequence":"additional","affiliation":[{"name":"Centre for Youth Mental Health, University of Melbourne , Melbourne, VIC 3052 ,","place":["Australia"]},{"name":"Centre for Mental Health and Brain Sciences, Swinburne University of Technology , Hawthorn, VIC 3122 ,","place":["Australia"]},{"name":"School of Psychology, University of Birmingham , Birmingham, B15 2TT ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayden","family":"Bryce","sequence":"additional","affiliation":[{"name":"Orygen, The National Centre for Excellence in Youth Mental Health , Parkville, VIC 3052 ,","place":["Australia"]},{"name":"Centre for Youth Mental Health, University of Melbourne , Melbourne, VIC 3052 ,","place":["Australia"]},{"name":"Alfred Mental and Addiction Health, Alfred Care Group, Bayside Health , Melbourne, VIC 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0640-4634","authenticated-orcid":false,"given":"Kelly","family":"Allott","sequence":"additional","affiliation":[{"name":"Orygen, The National Centre for Excellence in Youth Mental Health , Parkville, VIC 3052 ,","place":["Australia"]},{"name":"Centre for Youth Mental Health, University of Melbourne , Melbourne, VIC 3052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"2026082512161023600_ref1","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/schbul\/sbu047","article-title":"Recovery in psychosis: a Delphi study with experts by experience","volume":"40","author":"Law","year":"2014","journal-title":"Schizophr Bull"},{"key":"2026082512161023600_ref2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.schres.2024.02.035","article-title":"Response rates to sequential trials of antipsychotic medications according to algorithms or treatment guidelines in psychotic disorders. A systematic review and meta-analysis","volume":"268","author":"O'Donoghue","year":"2024","journal-title":"Schizophr Res"},{"key":"2026082512161023600_ref3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/eip.13436","article-title":"Cognitive health treatment priorities and preferences among young people with mental illness: the your mind, your choice survey","volume":"18","author":"Bryce","year":"2024","journal-title":"Early Interv Psychiatry"},{"key":"2026082512161023600_ref4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.schres.2023.10.019","article-title":"Cognition is a treatment priority for young people with psychosis: findings from the your mind. Your Choice survey","volume":"262","author":"Stainton","year":"2023","journal-title":"Schizophr Res"},{"key":"2026082512161023600_ref5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1037\/h0095655","article-title":"Recovery from mental illness: the guiding vision of the mental health service system in the 1990s","volume":"16","author":"Anthony","year":"1993","journal-title":"Psychosoc Rehabil J"},{"key":"2026082512161023600_ref6","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1176\/appi.ps.53.6.724","article-title":"Priorities of consumers, providers, and family members in the treatment of schizophrenia","volume":"53","author":"Fischer","year":"2002","journal-title":"Psychiatr Serv"},{"key":"2026082512161023600_ref7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/01.pra.0000419816.75752.65","article-title":"Valuation and attainment of treatment goals in schizophrenia: perspectives of patients, relatives, physicians, and payers","volume":"18","author":"Kuhnigk","year":"2012","journal-title":"J Psychiatr Pract"},{"key":"2026082512161023600_ref8","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1080\/09638237.2017.1370637","article-title":"The least worst option: user experiences of antipsychotic medication and lack of involvement in medication decisions in a UK community sample","volume":"27","author":"Morant","year":"2018","journal-title":"J Ment Health"},{"key":"2026082512161023600_ref9","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1093\/cid\/civ495","article-title":"Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR)","volume":"61","author":"Evans","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026082512161023600_ref10","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac140","article-title":"A desirability of outcome ranking analysis of a randomized clinical trial comparing seven versus fourteen days of antibiotics for uncomplicated gram-negative bloodstream infection","volume":"9:ofac140","author":"Howard-Anderson","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026082512161023600_ref11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1001\/jamapediatrics.2021.5547","article-title":"Short- vs standard-course outpatient antibiotic therapy for community-acquired pneumonia in children: the SCOUT-CAP randomized clinical trial","volume":"176","author":"Williams","year":"2022","journal-title":"JAMA Pediatr"},{"key":"2026082512161023600_ref12","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/epi4.12839","article-title":"The adaptation of the desirability of outcome ranking for interventional clinical trials in epilepsy: a novel consumer-led outcome measure","volume":"8","author":"Vivash","year":"2023","journal-title":"Epilepsia Open"},{"key":"2026082512161023600_ref13","doi-asserted-by":"publisher","first-page":"370.e1","DOI":"10.1016\/j.ajog.2023.09.016","article-title":"Desirability of outcome ranking for obstetrical trials: illustration and application to the ARRIVE trial","volume":"230","author":"Sandoval","year":"2024","journal-title":"Am J Obstet Gynecol"},{"key":"2026082512161023600_ref14","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cmi.2023.05.003","article-title":"Unlocking the DOOR\u2014how to design, apply, analyse, and interpret desirability of outcome ranking endpoints in infectious diseases clinical trials","volume":"29","author":"Ong","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2026082512161023600_ref15","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"2026082512161023600_ref16"},{"key":"2026082512161023600_ref17","volume-title":"Beyond Sticky","author":"McKercher","year":".  -  : ,   . , ,   . 2020"},{"key":"2026082512161023600_ref18","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1177\/10398562231174691","article-title":"The Australian Early Psychosis Collaborative Consortium (AEPCC): improving clinical care in early psychosis","volume":"31","author":"Thompson","year":"2023","journal-title":"Australas Psychiatry"},{"key":"2026082512161023600_ref19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1192\/bjp.2017.10","article-title":"Recovering Quality of Life (ReQoL): a new generic self-reported outcome measure for use with people experiencing mental health difficulties","volume":"212","author":"Keetharuth","year":"2018","journal-title":"Br J Psychiatry"},{"key":"2026082512161023600_ref20","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.eurpsy.2004.06.031","article-title":"Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence","volume":"19","author":"Lambert","year":"2004","journal-title":"Eur Psychiatry"},{"key":"2026082512161023600_ref21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"2026082512161023600_ref22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.64719\/pb.4069","article-title":"Which rating scales are regarded as \u2018the standard\u2019 in clinical trials for schizophrenia? A critical review","volume":"44","author":"Suzuki","year":"2011","journal-title":"Psychopharmacol Bull"},{"key":"2026082512161023600_ref23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4088\/JCP.13049su1c.02","article-title":"Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application","volume":"75","author":"Leucht","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"2026082512161023600_ref24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1177\/0269881107087976","article-title":"A new self-rating scale for detecting atypical or second-generation antipsychotic side effects","volume":"22","author":"Waddell","year":"2008","journal-title":"J Psychopharmacol"},{"key":"2026082512161023600_ref25","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S2352-4642(25)00063-X","article-title":"Co-design methodologies to develop mental health interventions with young people: a systematic review","volume":"9","author":"Chinsen","year":"2025","journal-title":"Lancet Child Adolescent Health"},{"key":"2026082512161023600_ref26","doi-asserted-by":"publisher","first-page":"701312","DOI":"10.3389\/fpsyt.2021.701312","article-title":"Designed to clash? Reflecting on the practical, personal, and structural challenges of collaborative research in psychiatry","volume":"12","author":"Beeker","year":"2021","journal-title":"Front Psych"},{"key":"2026082512161023600_ref27","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/15710882.2024.2349578","article-title":"Creating the conditions for collaborative decision-making in co-design","volume":"20","author":"Thorburn","year":"2024","journal-title":"CoDesign"},{"key":"2026082512161023600_ref28","author":"McPin Foundation","year":"2022"}],"container-title":["Schizophrenia Bulletin Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizbullopen\/advance-article-pdf\/doi\/10.1093\/schizbullopen\/sgag033\/70496816\/sgag033.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizbullopen\/article-pdf\/7\/1\/sgag033\/70496816\/sgag033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizbullopen\/article-pdf\/7\/1\/sgag033\/70496816\/sgag033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:16:20Z","timestamp":1787674580000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizbullopen\/article\/doi\/10.1093\/schizbullopen\/sgag033\/8752682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,22]]}},"URL":"https:\/\/doi.org\/10.1093\/schizbullopen\/sgag033","relation":{},"ISSN":["2632-7899"],"issn-type":[{"value":"2632-7899","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"sgag033"}}